Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients ...

Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function ...

In this week’s edition of the biotech bi-weekly, learn more about Thermo Fisher’s new system for automating complex sample ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

To increase your platelet count, you can adjust your diet and vitamin regimen to include more vitamin C, folate, iron, and other essential nutrients. This is extremely helpful if you have a low ...

[2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the platelet surface GP IIb/IIIa. A more recently approved drug ...

The pathogenesis of suboptimal platelet function is multifactorial. Platelets do not function well if there are too many or too few platelets; also the platelets can be present in the appropriate ...

Platelet spreading and clot contraction are regulated by distinct pathways, contrary to previous beliefs that they shared a common pathway. This discovery reveals that different signaling ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma ...